Similarly to CMAP, it is reduced in patients with SMA type 1 and 2, correlated with SMA type, age, and SMN2 copy number [140, 141] and improved in children treated with onasemnogene abeparvovec [142] and nusinersen [143]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.